Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewcelX ( (NCEL) ) has provided an update.
On April 1, 2026, Zurich-based NewcelX Ltd. announced it had entered into definitive securities purchase agreements for a $1.35 million private placement priced at $2.75 per share, a 30% premium to its March 31 closing price. The deal covers 490,907 common shares or equivalents and five-year warrants for up to 687,270 shares at $3.025, with participation from existing investors and an expected closing around April 15, 2026.
NewcelX plans to combine the net proceeds from this financing with its previously announced $25 million equity line to fund development of NCEL-101, its lead Type 1 Diabetes program in collaboration with Eledon Pharmaceuticals, as well as its broader pipeline and general corporate purposes. The structure of the deal, including a 60-day restriction on additional equity issuance and a commitment to register the resale of the securities, underscores investor confidence in the company’s strategy and provides incremental runway in a challenging biotech capital market.
More about NewcelX
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing stem cell-derived therapies for Type 1 Diabetes. Built on a human pluripotent stem cell platform, its lead candidate NCEL-101 aims to restore functional insulin production via scalable, off-the-shelf cell replacement, integrating cell therapy, immune protection and translational science to address significant unmet medical needs.
Average Trading Volume: 88,624
Technical Sentiment Signal: Sell
Current Market Cap: $9.66M
For a thorough assessment of NCEL stock, go to TipRanks’ Stock Analysis page.